Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open Label, First-in-human Study of TR1801-ADC, an Antibody Drug Conjugate (ADC), in Patients With Select Solid Tumors Expressing c-Met

NCT03859752 is registered in ClinicalTrials.gov with Open Innovation Partners, Inc. as lead sponsor.

NCT NCT03859752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03859752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open Label, First-in-human Study of TR1801-ADC, an Antibody Drug Conjugate (ADC), in Patients With Select Solid Tumors Expressing c-Met
Lead sponsor
Open Innovation Partners, Inc.
Phase
Phase 1
Overall status
Suspended
Start date
August 14, 2019
Completion date
December 31, 2023
Enrollment
15 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

unspecified adult solid tumor, protocol specific